In this stepwise meta-analysis of 3 landmark ICH trials, intensive BP reduction did not demonstrate a significant benefit in either deep or lobar ICH. Although our estimates did not reach statistical significance, the direction of effect in deep ICH and the substantial heterogeneity across trials, particularly with the inclusion of INTERACT3, limit firm conclusions. Given these uncertainties and the biological distinctions between deep and lobar ICH, future well-powered studies specifically designed to test whether intensive BP reduction has differential effects by hematoma location are warranted.
Clocchiatti-Tuozzo et al. (Fri,) studied this question.